Teladoc Health (TDOC)
(Delayed Data from NYSE)
$9.23 USD
-0.28 (-2.94%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $9.27 +0.04 (0.43%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.23 USD
-0.28 (-2.94%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $9.27 +0.04 (0.43%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Teladoc Health Q3 Loss Narrows on Strong Integrated Care Unit
by Zacks Equity Research
TDOC expects 2024 U.S. Integrated Care Members to remain within 93.5-94.5 million.
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 34.48% and 1.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Teladoc (TDOC) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Teladoc (TDOC) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Teladoc (TDOC) settling at $8.60, representing a -0.92% change from its previous close.
Strength Seen in MultiPlan (MPLN): Can Its 9.0% Jump Turn into More Strength?
by Zacks Equity Research
MultiPlan (MPLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc (TDOC) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Teladoc (TDOC) reachead $8.41 at the closing of the latest trading day, reflecting a -0.71% change compared to its last close.
Teladoc Stock Rises 12% as Jefferies Boosts Price Target on BetterHelp
by Zacks Equity Research
TDOC's stock benefits from improving web traffic in its BetterHelp platform.
Why Teladoc (TDOC) Outpaced the Stock Market Today
by Zacks Equity Research
Teladoc (TDOC) closed at $8.16 in the latest trading session, marking a +0.87% move from the prior day.
Why Teladoc (TDOC) Outpaced the Stock Market Today
by Zacks Equity Research
Teladoc (TDOC) closed at $7.25 in the latest trading session, marking a +0.83% move from the prior day.
Teladoc Stock Near 52-Week Low: Is it Healthy Enough to Invest?
by Zacks Equity Research
TDOC is well positioned to grow in the long run on the back of expanding product offerings, memberships, AI integration, business diversification and global expansions.
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Here's Why Teladoc (TDOC) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $7.17, denoting a +0.99% change from the preceding trading day.
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Teladoc (TDOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 22.22% and 1.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Teladoc (TDOC) Q2 Earnings Navigate BetterHelp Profit Woes?
by Zacks Equity Research
Teladoc's (TDOC) second-quarter results are likely to reflect lower advertising and marketing expenses.
Countdown to Teladoc (TDOC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Teladoc (TDOC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.30, moving +1.2% from the previous trading session.
Teladoc (TDOC) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.39, moving +0.21% from the previous trading session.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc (TDOC) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Teladoc (TDOC) closed at $10.14 in the latest trading session, marking a -0.1% move from the prior day.
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
by Zacks Equity Research
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.